Here's the latest reshuffling of top holdings by Soros Fund Management.
Organovo (ONVO) announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured ...
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...
Zacks Small Cap Research on MSN16d
ONVO Releases Encouraging Quarterly ResultsONVO READ THE FULL ONVO RESEARCH REPORT Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments ...
Organovo stock opened at $0.44 on Friday. The company’s 50-day moving average price is $0.51 and its two-hundred day moving average price is $0.73. The stock has a market cap of $6.35 million ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Organovo Holdings Inc. (ONVO) on Friday reported a loss of $2.5 million in its fiscal second quarter. The San Diego-based company said it had a loss of 14 ...
The presentation entitled “Pharmacokinetics, Safety and Efficacy of the Novel Non-bile Acid FXR Agonist FXR314 in Patients with Metabolic Dysfunction-Associated Steatohepatitis: Results from a Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback